Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 202


Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection.

Leigh Brown AJ, Frost SD, Good B, Daar ES, Simon V, Markowitz M, Collier AC, Connick E, Conway B, Margolick JB, Routy JP, Corbeil J, Hellmann NS, Richman DD, Little SJ.

J Virol. 2004 Mar;78(5):2242-6.


Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.

Martinez-Picado J, Wrin T, Frost SD, Clotet B, Ruiz L, Brown AJ, Petropoulos CJ, Parkin NT.

J Virol. 2005 May;79(10):5907-13.


Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.

Bally F, Martinez R, Peters S, Sudre P, Telenti A.

AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1209-13.


Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

Kaufmann GR, Suzuki K, Cunningham P, Mukaide M, Kondo M, Imai M, Zaunders J, Cooper DA.

AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):487-97.


Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.

Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Kräusslich HG, Hance AJ, Clavel F; ANRS 109 Study Group.

PLoS Pathog. 2009 Mar;5(3):e1000345. doi: 10.1371/journal.ppat.1000345. Epub 2009 Mar 20.


Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.

Garriga C, Pérez-Elías MJ, Delgado R, Ruiz L, Nájera R, Pumarola T, Alonso-Socas Mdel M, García-Bujalance S, Menéndez-Arias L; Spanish Group for the Study of Antiretroviral Drug Resistance.

J Med Virol. 2007 Nov;79(11):1617-28.


Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, Simon A, Katlama C, Costagliola D, Calvez V, Marcelin AG.

J Infect. 2007 Apr;54(4):367-74. Epub 2006 Jul 26.


Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V.

Antimicrob Agents Chemother. 2008 Sep;52(9):3237-43. doi: 10.1128/AAC.00133-08. Epub 2008 Jul 14.


Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

Verheyen J, Litau E, Sing T, Däumer M, Balduin M, Oette M, Fätkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R.

Antivir Ther. 2006;11(7):879-87.


Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.

Jinnopat P, Isarangkura-na-ayuthaya P, Utachee P, Kitagawa Y, de Silva UC, Siripanyaphinyo U, Kameoka Y, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):320-8. doi: 10.1097/QAI.0b013e3181b4b18c.


Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.

Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13.


Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.

Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP.

J Virol. 2002 Aug;76(15):7398-406.


Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.

van Maarseveen NM, Wensing AM, de Jong D, Taconis M, Borleffs JC, Boucher CA, Nijhuis M.

J Infect Dis. 2007 Feb 1;195(3):399-409. Epub 2006 Dec 29.


Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

Nijhuis M, Wensing AM, Bierman WF, de Jong D, Kagan R, Fun A, Jaspers CA, Schurink KA, van Agtmael MA, Boucher CA.

J Infect Dis. 2009 Sep 1;200(5):698-709. doi: 10.1086/605329.


Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.

Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, Voujon D, Bossi P, Ktorza N, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V.

J Med Virol. 2004 Sep;74(1):16-20.


Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.

Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT.

Virology. 2000 Sep 30;275(2):318-22.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk